ABSTRACT
Human samples of patients with chronic pericarditis and appropriate control subjects were stained for the inflammasome components. A mouse model of pericarditis was developed through the intrapericardial injection of zymosan A. Different inflammasome blockers were tested in the mouse model. Patients with pericarditis presented an intensification of the inflammasome activation compared with control subjects. The experimental model showed the pathological features of pericarditis. Among inflammasome blockers, NLRP3 inflammasome inhibitor, anakinra, and interleukin-1 trap were found to significantly improve pericardial alterations. Colchicine partially improved the pericardial inflammation. An intense activation of the inflammasome in pericarditis was demonstrated both in humans and in mice.
Subject(s)
Aminobutyrates/therapeutic use , Angiotensin II Type 1 Receptor Blockers/therapeutic use , Heart Failure/drug therapy , Protease Inhibitors/therapeutic use , Tetrazoles/therapeutic use , Aminobutyrates/adverse effects , Angiotensin II Type 1 Receptor Blockers/adverse effects , Biphenyl Compounds , Clinical Trials as Topic , Comorbidity , Drug Combinations , Heart Failure/diagnosis , Heart Failure/mortality , Heart Failure/physiopathology , Humans , Neprilysin/antagonists & inhibitors , Protease Inhibitors/adverse effects , Recovery of Function , Risk Factors , Tetrazoles/adverse effects , Treatment Outcome , ValsartanSubject(s)
Aminobutyrates/therapeutic use , Angiotensin II Type 1 Receptor Blockers/therapeutic use , Heart Failure/therapy , Protease Inhibitors/therapeutic use , Tetrazoles/therapeutic use , Aminobutyrates/adverse effects , Angiotensin II Type 1 Receptor Blockers/adverse effects , Biphenyl Compounds , Clinical Trials as Topic , Drug Combinations , Evidence-Based Medicine , Heart Failure/diagnosis , Heart Failure/mortality , Heart Failure/physiopathology , Hospitalization , Humans , Neprilysin/antagonists & inhibitors , Protease Inhibitors/adverse effects , Recovery of Function , Tetrazoles/adverse effects , Treatment Outcome , ValsartanABSTRACT
Cirrhotic cardiomyopathy is a clinical syndrome in patients with liver cirrhosis characterized by an abnormal and blunted response to physiologic, pathologic, or pharmacologic stress but normal to increased cardiac output and contractility at rest. As many as 50% of cirrhotic patients undergoing liver transplantation show signs of cardiac dysfunction, and 7% to 21% of deaths after orthotopic liver transplantation result from overt heart failure. In this review, we critically evaluate the existing literature on the pathophysiology and clinical implications of cirrhotic cardiomyopathy.
